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Introduction: Very recently, we have found a novel fusion product
between the echinoderm microtubule-associated protein-like4
(EML4) and the anaplastic lymphoma kinase (ALK) in non-small
cell lung cancers (NSCLCs). Tumors featuring EML4-ALK fusion
constitute one subtype of NSCLC that might be highly sensitive to
ALK inhibitors. Herein, we present results of a first large scale study
of EML4-ALK fusion in lung cancers.
Methods: Using reverse transcription-polymerase chain reaction for
EML4-ALK fusion mRNA, we investigated 149 lung adenocarci-
nomas, 48 squamous cell carcinomas, 3 large-cell neuroendocrine
carcinomas, and 21 small-cell carcinomas. For EML4-ALK-positive
cancers, we further investigated the presence of ALK fusion proteins
by immunohistochemistry.
Results: Five of 149 adenocarcinomas (3.4%) showed EML4-ALK
fusion mRNA, this being totally lacking in carcinomas of other types
(0/72). In all the fusion-positive cases, ALK fusion protein could be
detected in the cytoplasm immunohistochemically. The five fusion
cases featured two EML4-ALK variant 1 fusions and three variant 2
fusions. Histologically, both variant 1 cases were mixed type ade-
nocarcinomas, showing papillary with bronchioloalveolar compo-
nents. Interestingly, all three variant 2 cases were acinar adenocar-
cinomas, the link being statistically significant (p  0.00018). None
of the five fusion-positive cases demonstrated any mutations of
EGFR or KRAS, pointing to a mutually exclusive relationship (p 
0.014). There was no association with smoking habits.
Conclusions: In the present first investigation of EML4-ALK fusion
in a large study of lung cancers (5/221), we found an interesting
histotype-genotype relationship. Furthermore, we could detect the
fusion protein by immunohistochemistry, pointing to possible clin-
ical applications.
Keywords: Lung cancer, EML4-ALK, RT-PCR, Immunohisto-
chemistry, Histology.
(J Thorac Oncol. 2008;3: 13–17)
Lung cancer is the leading cause of cancer death in men andwomen worldwide. Identification of activating mutations
of the epidermal growth factor receptor (EGFR) is one of the
most intriguing recent discoveries in the field of lung cancer
research.1,2 EGFR mutations are present in one subtype of
lung adenocarcinoma, and tumors with this mutation have
been shown to be highly sensitive to gefitinib (Iressa). The
subtype is prevalent in women, and in patients of Japanese
and other Asian ethnicity, especially in nonsmokers.1,3,4 With
the move to personalized cancer therapy, we need to under-
stand oncologic biology at the molecular level in individual
lesions to be able to treat cancers with specific molecular-
targeting strategies.
Very recently, we have found a novel transforming
fusion gene resulting from linkage between the echinoderm
microtubule-associated protein-like4 (EML4) and the ana-
plastic lymphoma kinase (ALK) genes in non-small cell lung
cancers (NSCLCs).5 Tumors featuring EML4-ALK fusion
constitute one subtype of NSCLC which might be highly
sensitive to ALK inhibitors. The fusion gene is formed by a
small inversion within chromosome 2p. EML4 on chromo-
some 2p21 belongs to the family of echinoderm microtubule-
associated protein-like proteins, localized in the cytoplasm,
and is necessary for correct microtubule formation.6,7 ALK
on chromosome 2p23 codes for a receptor tyrosine kinase and
was first identified as a fusion partner of nucleophosmin
(NPM) in anaplastic large-cell lymphomas (ALCLs) with a
t(2;5) chromosome rearrangement.8,9 NPM is an RNA-bind-
ing protein that transports ribonucleoproteins between the
nucleus and cytoplasm and contributes a nuclear localization
signal to the NPM-ALK fusion protein.10 Other chromosome
translocations involving the ALK locus have been identified
in ALCLs11,12 as well as in inflammatory myofibroblastic
tumors (IMTs).13 The fusion point of ALK is conserved
among all these chimeric tyrosine kinases including EML4-
ALK, resulting in fusion of the entire intracellular kinase
domain of ALK to the different partners.14
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Herein, we present a first large scale study of EML4-
ALK fusion in lung cancers, including SCLCs. Furthermore,
we detail clinicopathologic and genetic features of fusion-
positive lung cancers.
PATIENTS AND METHODS
Clinical Samples and RNA Extraction
This study was conducted with clinical samples from 149
lung adenocarcinomas, 48 squamous cell carcinomas, 3 large
cell neuroendocrine carcinomas, and 21 SCLCs. Many of these
samples were previously examined and reported.15–21 For exam-
ple, most adenocarcinomas were examined as to their mRNA
levels of PTEN19or HOXB2,21 and some adenocarcinomas were
examined as to their let-7 microRNA levels.20 All were collected
with ethical committee approval and informed consent from
patients undergoing surgery at the Cancer Institute Hospital,
Tokyo, Japan, between May 1995 and August 2004. Histologic
diagnosis was according to World Health Organization classifi-
cations22 as well as to differentiation-grading criteria for adeno-
carcinomas of the Japanese Lung Cancer Society.23,24 All lesions
were grossly dissected and snap-frozen in liquid nitrogen within
20 minutes of removal and stored at 80°C until total RNA
extraction and purification using an RNeasy Mini Kit (QIA-
GEN, Valencia, CA). RNA quality and absence of genomic
DNA contamination were checked by formaldehyde agarose gel
electrophoresis.
Reverse Transcription-Polymerase Chain
Reaction and Sequencing Analysis
Total RNAs were reverse transcribed with random
primers and SuperScript III reverse transcription (Invitrogen,
Carlsbad, CA). To detect fusion transcripts derived from EML4
and ALK, reverse transcription-polymerase chain reaction (RT-
PCR) experiments were carried out with primers Fusion-RT-S
(5-GTGCAGTGTTTAGCATTCTTGGGG-3) and Fusion-
RT-AS (5-TCTTGCCAGCAAAGCAGTAGTTGG-3). We
used PCR primers 5-GTCAGTGGTGGACCTGACCT-3 and
5-TGAGCTTGACAAAGTGGTCG for the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as an internal control. For
PCR of the fusion transcripts, after initial denaturation at
94°C for 10 minutes, 32 cycles each consisting of denatur-
ation at 94°C for 1 minute, annealing at 60°C for 1 minute,
and strand elongation at 72°C for 1 minute were performed,
followed by a final elongation at 72°C for 10 minutes. For
GAPDH, amplification was performed for 35 cycles with
denaturation for 1 minute at 94°C, primer annealing for 30
seconds at 58°C, and elongation for 30 seconds at 72°C. PCR
was performed using AmpliTaq Gold (Applied Biosystems,
Foster City, CA) and amplified fragments were subjected to
direct sequence analysis.
Immunohistochemical Analysis
A representative tissue block from each lesion was se-
lected, and 4-m tissue sections were routinely deparaffinized in
xylene and rehydrated through graded ethanols. Immunohisto-
chemical staining was performed using the EnVision DAB
system (DAKO, Carpinteria, CA) and a mouse monoclonal
anti-ALK antibody (ALK1, DAKO, 1:20).
DNA Extraction and Mutation Analysis of EGFR
and KRAS
Of 149 patients with adenocarcinomas, both EGFR and
KRAS data were available for 62 and EGFR data alone for a
further 12. DNA extraction and mutation analysis of EGFR
and KRAS were performed as described previously.19
Analysis of Clinicopathologic Parameters
Survival data were analyzed by the log-rank test using
cancer death-specific survival data. We analyzed statistical
correlations for the other clinicopathologic features using the
Student t test, Fisher exact test, or 2 test as appropriate. The
two-sided significance level was set at p  0.05.
RESULTS
Using RT-PCR for EML4-ALK fusion mRNA, we inves-
tigated the presence of the EML4-ALK translocation in 221 lung
cancers (Table 1). Five of 149 adenocarcinomas (3.4%) featured
EML4-ALK fusion mRNA, whereas other types of carcinoma
were all negative (0/72) (Figure 1). Of the five fusion-positive
cases, two had EML4-ALK variant 1 and three had variant 2.5
The fusions were confirmed by direct sequencing.
Histologically, both the variant 1 cases were mixed
type adenocarcinomas, papillary with bronchioloalveolar
components (Figure 2A). Interestingly, all three variant 2
cases were acinar adenocarcinomas, moderately or poorly
differentiated (Figure 2B). The link between variant 2 and
acinar morphology was statistically significant (p  0.00018,
Fisher exact test).
Immunohistochemically, all the five fusion-positive
cases showed ALK fusion protein in the cytoplasm (Figure 3)
in line with the absence of any nuclear localization signal in
the EML4 gene. We cannot rule out the possibility of detect-
ing endogenous ALK protein.
Table 2 summarizes details for clinicopathologic and
genetic features of the fusion-positive lung cancers. Geneti-
cally, all lacked mutations of EGFR or KRAS (p  0.014 as
TABLE 1. EML4-ALK Fusion and Histology
Histology Total EML4-ALK() EML4-ALK()
Adenocarcinoma 149 5 (3.4%) 144 (97%)
Subtype
Adenocarcinoma with
mixed subtype
89 2a (2.3%) 87 (98%)
Papillary adenocarcinoma 35 0 (0%) 35 (100%)
Acinar adenocarcinoma 18 3b (17%) 15 (83%)
Solid adenocarcinoma
with mucin
4 0 (0%) 4 (100%)
Bronchioloalveolar
carcinoma
3 0 (0%) 3 (100%)
Squamous cell carcinoma 48 0 (0%) 48 (100%)
Large cell neuroendocrine
carcinoma
3 0 (0%) 3 (100%)
Small cell carcinoma 21 0 (0%) 21 (100%)
a Variant 1; Fisher exact test, p  0.66 (Adenocarcinoma with mixed subtype vs.
the other adenocarcinomas).
b Variant 2; Fisher exact test, p  0.00018 (Acinar adenocarcinoma vs. the other
adenocarcinomas).
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compared with expectation). Patients with EML4-ALK fu-
sion-positive tumors were younger than those without by 4
years, though this was not statistically significant. One patient
was 43 years old and died 4 months after surgery (variant 2,
acinar adenocarcinoma, poorly differentiated, clinical stage-
IV, cerebellar metastasis). The other four patients were 58 to
66 years old and are alive now. There was no association
between EML4-ALK fusion and smoking habits, although
the sample numbers were small (p  0.77).
We analyzed the survival data statistically with the log
rank test, but there was no prognostic significance of EML-
ALK fusion (p  0.84).
DISCUSSION
In the present first large scale study of a novel EML4-
ALK fusion in 221 lung cancers including 21 SCLCs, 5 of
149 adenocarcinomas (3.4%) proved positive for fusion
mRNA and fusion protein. Interesting histotype-genotype
relationships were observed. Although both variant 1 cases
were papillary adenocarcinomas with bronchioloalveolar
components, all the three variant 2 cases were of acinar type.
Furthermore, none of these lesions had mutations in EGFR or
KRAS, pointing to a mutually exclusive relationship.
The ALK gene encodes a transmembrane receptor ty-
rosine kinase that belongs to the insulin receptor superfamily
and is most similar to leukocyte tyrosine kinase.25 Postnatal
ALK expression is normally restricted to a few scattered cells
in the nervous system,26 but chromosomal translocations
involving the ALK are characteristic of ALCLs and IMTs.
An increasing number of translocation patterns have been
identified and other neoplasms with similar changes have
been identified, such as large B-cell lymphomas.27 Very
recently, we described a novel subpopulation of NSCLCs
with ALK translocations,5 and it is very likely that other
examples will be identified by further searches. ALK-positive
ACLCs predominantly affect younger patients and, if treated
with chemotherapy, have a more favorable prognosis than
their negative counterparts.28 Similarly ALK-positive IMTs
primarily affect younger patients.13 In this study, ALK-
positive lung adenocarcinomas were also found in younger
patients when compared with ALK-negative tumors. Espe-
cially, one of the five patients was 43 years old, very young
for lung adenocarcinomas. Although one example is insuffi-
cient for discussion, ALK-positive adenocarcinomas might
include younger patients. Although survival data analysis
demonstrated no significant difference between ALK-positive
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FIGURE 1. RT-PCR for EML4-ALK fusion
mRNA. All the 5 fusion-positive cases and fu-
sion negative cases of all the histologic sub-
types examined are shown. RT-PCR results for-
GAPDH mRNA are also included as an internal
control. AC, adenocarcinoma; mixed, adeno-
carcinoma with mixed subtype; papillary, papil-
lary adenocarcinoma; acinar, acinar adenocarci-
noma; solid, solid adenocarcinoma with mucin;
BAC, bronchioloalveolar carcinoma; SCC, squa-
mous cell carcinoma; LCNEC, large cell neu-
roendocrine carcinoma; SCLC, small cell lung
carcinoma; NTC, no template control.
FIGURE 2. Representative examples of histologic features.
Both the 2 variant 1 cases were mixed type adenocarcino-
mas, with papillary and bronchioloalveolar components (A).
All 3 variant 2 cases were acinar adenocarcinomas (B).
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and negative adenocarcinomas, this might be due to the small
number of positive cases. Whatever is the cause, for ALK-
positive tumors, molecular targeted therapies including ALK
inhibitors may be used.
ALK1 antibody, used in the immunohistochemical
analysis, detects the cytoplasmic region of the ALK protein
and also detects the full-length endogenous ALK protein.
When we detect the positive staining of ALK1, three possi-
bilities are considerable: (i) EML4-ALK fusion protein, (ii)
endogenous full-length ALK protein, or (iii) ALK fusion
protein with another partner. The five EML4-ALK fusion
cases immunostained positive for ALK with variable inten-
sity. Endogenous full-length ALK protein might, however, be
also detected by immunohistochemistry. Therefore, EML4-
ALK fusion should be confirmed by RT-PCR practically,
although the immunohistochemistry can be used for the
screening purpose.
In conclusion, we here found a minor subpopulation of
lung adenocarcinomas featuring EML4-ALK fusion with
evidence of histotype-genotype relationships. Furthermore,
we could detect the fusion protein by immunohistochemistry,
pointing to clinical applications.
FIGURE 3. Representative examples of immu-
nohistochemical features. Both adenocarcino-
mas with mixed subtype (A) with the variant 1
EML4-ALK fusion and acinar adenocarcinomas
(B) with the variant 2 show ALK fusion protein
in their cytoplasm.
TABLE 2. Relationship between EML4-ALK Fusion and Clinicopathologic and
Genetic Features in Lung Adenocarcinomas
Variables category No. samples (%)
EML4-ALK fusion
p() (n  5) () (n  144)
Age (yr; mean  SD) 149 59.4  9.7 63.4  8.7 0.31a
Sex 0.87b
Male 80 (54%) 2 (40%) 78 (54%)
Female 69 (46%) 3 (60%) 66 (46%)
Smoking habit 0.77b
Never 65 (44%) 3 (60%) 62 (43%)
Smoker 84 (56%) 2 (40%) 82 (57%)
Tumor size 0.40b
30mm 77 (52%) 4 (80%) 73 (51%)
30 mm  72 (48%) 1 (20%) 71 (49%)
Differentiation 0.73c
Well 48 (32%) 1 (20%) 47 (33%)
Moderate 62 (42%) 2 (40%) 60 (42%)
Poor 39 (26%) 2 (40%) 37 (26%)
EGFR 0.034b
Mutation () 41 (55%) 0 (0%) 41 (59%)
Mutation () 33 (45%) 5 (100%) 28 (41%)
KRAS 0.92b
Mutation () 7 (11%) 0 (0%) 7 (12%)
Mutation () 55 (89%) 5 (100%) 50 (88%)
EGFR or KRAS 0.014b
Mutation () 38 (61%) 0 (0%) 38 (67%)
Mutation () 24 (39%) 5 (100%) 19 (33%)
p-Stage 0.73b
I 63 (43%) 2 (40%) 61 (43%)
II–IV 85 (57%) 3 (60%) 82 (57%)
Percentages may not total 100, because of rounding.
a Student t test.
b Fisher exact test.
c Yates 2 test.
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